Claim OwnershipEY Health Sciences & Wellness podcast series
Subscribed: 24Played: 71
Subscribe
© EY
Description
The EY Health Sciences and Wellness Experience podcast explores the age of "Health Experience." All who use and touch the heath care value chain will soon demand a service that provides a more personalized and enhanced outcome. Join us and our guests, as we expand the traditional definitions of innovation to meet ever growing needs and expectations.
20 Episodes
Reverse
In this episode of the EY Health Sciences and Wellness Experience podcast, host Patrick T. O'Sullivan discusses how AI is currently being used to support pharmaceutical manufacturing and supply chain.
In this episode of the EY Health Sciences and Wellness Experience Podcast, Aloha McBride and her guests explore health inequity, sustainable change and environmental impact of the health industry. Our panel of experts discuss the evolution of sustainability in health. The explore where organizations can start on their sustainability journey, how they can create sustainable change, and reduce climate impact. Through exploring global examples. they show how data and analytics play a key role in long-term strategies and regulatory compliance. Join in and discover the steps to lessen environmental impact, leverage data for sustainability, and form valuable partnerships. Drive behaviour change, avoid inaction risks, and embark on a transformative sustainability journey in healthcare.
In today's episode we focus on the EY report on the Pharma supply chains of the future, and discuss the impact of global events and how a new supply chain model can emerge in the pharma industry. The speakers discuss the future of pharmaceutical supply chains in the wake of the COVID-19 pandemic and other geopolitical events and shifts that are unfolding around us. The discussion covers the impact of global events that have led to a revaluation of globalized supply chain models and a creation of a new, optimised model where the end-to-end visibility is a crucial factor. Join us as we explore the future of pharmaceutical supply chains and their adaptability in the face of challenges.
In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact. Together they review the growing importance of sustainable health solutions, ESG in healthcare and sustainability reporting in the Health Sciences and Wellness industry. Learn how ESG reporting and the information flow that helps businesses successfully engage with their stakeholders. The conversation also explores global use cases, the significance of banking for impact, and the gaps in impact measurement that need attention in the coming years. Uncover the multitude of metrics available in sustainability reporting, the growing importance of sustainability metrics, and their potential to drive transformative conversations.
In this episode of the EY Health Sciences and Wellness Experience podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, talks with Nancy Flores, Executive Vice President & Chief Information and Technology Officer for McKesson Corporation and look into innovation in healthcare and health care data science. They discuss the unique complexities of healthcare – a sector with new entrants, new regulations, consolidation, pricing pressures, and an ageing population that needs ever more healthcare. But alongside the complexities, there are opportunities for disruptive innovation as well as technology and data. The conversation also covers the challenge of recruiting and retaining data scientists and how to connect their skills and talents to patient health outcomes. Finally, they discuss the excitement and importance of using technology and data to support healthcare and the quality of patients' lives.
In this episode of the EY Health Sciences and Wellness Experience podcast we focus on women in health. Join Pamela Spence, EY Global Health Sciences and Wellness Leader, as she speaks with Trecilla Lobo, SVP, People, BenevolentAI, Rabia Khan, Founder/CEO, Ladder Therapeutics, and Samin Saeed, UK Chief Scientific Officer and Medical Director, Novartis. Together they discuss their own unique career journeys within the health sciences and wellness industry. They also share with us those critical lessons they have learned from their mentors and supporters along the way. They offer valuable insights on med-tech innovations, diversity in tech and in med-tech companies, changes in the medical sector. This inspiring dialogue challenges us to reflect on our own experiences and ask ourselves, "Are we doing enough to foster the next generation of leaders?" Tune in and be inspired by the incredible female leadership present in the industry today.
In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, Jackie Hunter, Board Director of Benevolent AI and Ridwaan Jhetam, VP Global Medical for Haematology, BMS, discuss the importance of data science in healthcare and how it can help redesign the health experience and the future of health. In this wide-ranging discussion, the expert panel approach the topic of health economy and smart health from their different perspectives. Whether you're a doctor or researcher, a programmer or a CIO, whether you work in the field or you're just looking in from outside, you'll find this an insightful and timely listen.
There are 2,600 gen and cell therapy clinical trials taking place this year. In the US alone, this could translate up to 20 new therapy approvals in 2022, which presents a clear opportunity to make more life-saving therapies available to a greater number of individuals. As the evolution of medicine continues, the future looks promising for advancements in cell and gene therapy. In this podcast, Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader for EY, talks to Tamie Joeckel – ICON's Cell and Gene Therapy Global Business Lead, as they discuss the use of technology in medicine and what makes an increase in the volume of clinical trials, including cgt clinical trials, and an acceleration of the clinical trial process significant.
In this episode, we delve into the global challenge of addressing health inequality with Dr. Yele Aluko, EY Chief Medical Officer, and Dr. David Rhew, Microsoft Chief Medical Officer. As experienced physicians, they share their passion for finding opportunities to provide health equity and discuss the root causes of disparities and how unbiased digital medicine can help. We learn that health care disparity starts much earlier than diagnosis and treatment, with low minority enrolment rates in clinical trials leading to results that don't reflect the population. The COVID-19 pandemic has highlighted health disparities across populations, and we need strategic insight from the health care value chain to identify healthcare gap and develop tactics and solutions that will close them. Join us as we discuss the evolution of medicine, the importance of inclusive clinical trials, and how digital solutions can help us close the healthcare gap.
In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of "Health Experience" and the disruptive health innovation emerging in the aftermath of the covid 19 pandemic. The Covid 19 impact on healthcare was immense and Health Sciences and Wellness industry has never been as "front and centre" in our lives as it has been in this last year. As all of us, worldwide, ride the various waves of the pandemic, our Health Sciences and Wellness industry has taken the lead in healthcare analytics and healthcare innovation and giving care to those who have needed it most. We have also seen a monumental collaborative R&D effort – at a scale never witnessed before. Tune in as we explore the various trends in healthcare innovation, technology and analytics that are reshaping the Health Sciences and Wellness Industry and driving the evolution of the smart health systems of the future that can deliver an improved Health Experience.
The COVID-19 pandemic provides the ‘burning platform’ for accelerating the data agenda. New data-based tools and technologies make a more personalized approach to health and wellness possible. The world has never needed this more than now. While companies and organizations long recognized the potential of new tools to capture and use data to transform health, they lacked the “burning platform” to fuel this change. The COVID-19 pandemic and the global disruption it caused has demonstrated that organizations can become more resilient, agile and innovative if they shift to digitally enabled business models with data at the core.
New technologies are creating new opportunities, but they are also creating unknown and unquantified risks. Organizations that understand what it takes to succeed with new cost and revenue models, new value propositions, and new relationships with the right partners, will start to reshape the health market. In this edition of New Horizons, we explore four areas where this process of reshaping is underway.
With dealmaking a cornerstone of the growth strategy, 2020 will be a robust year for life sciences M&A. To succeed, companies must continue to focus their business models, close near term growth gaps and invest in future innovation.
In the EY 2019 Pulse of the industry, we review the performance of the global medical technology industry. The industry continues to grow, but its long-term outlook is at risk from underinvestment in R&D and lack of collaboration between industry providers, payers and patients.
Nothing can change if minds do not. How can we make common ground the foundation for real change? As technology increasingly takes on the role of management, more emphasis falls on the role of leaders. Neuroscience is uncovering approaches to influence that leaders can use to enlist others to share their beliefs and commitments. In this episode of The Better Question, EYQ Fellow Chris Meyer is joined by Tali Sharot, professor of cognitive neuroscience at University College London and EYQ Fellow, and Seth Godin, entrepreneur and author of numerous bestsellers, including Permission Marketing: Turning Strangers into Friends and Friends into Customers.
Data is the driving force underpinning the Fourth Industrial Revolution and the emergence of new business models. In health care, the goal is to use data to deliver interventions more proactively and in more personalized ways, ultimately leading to better health outcomes and a shift to prevention. Five trends are leading the rise of a new, data-centric approach to health care. An organization’s ability to generate value depends on how effectively it can unlock the power of data and generate insights by connecting, combining and securely sharing data at greater scale than ever before. Learn more by visiting us at ey.com/lifesciences Additional audiobook formats include iTunes | Google Play Music | Spotify
Over the past three decades, life sciences companies have used their biological and chemical know-how to create significant value for themselves, their shareholders and most importantly patients. In today’s fast-changing environment, it’s very likely that life sciences companies will need access to an array of medical and non-medical data to demonstrate value to their stakeholders. In the latest 2019 EY M&A Firepower report, we explore the dealmaking strategies life sciences should prioritize to generate growth. This year’s findings show that life sciences companies must accelerate their agendas on the creation of focused business models and the acquisition of disruptive, digital capabilities. Learn more by visiting us at ey.com/firepower Additional audiobook formats include iTunes | Google Play Music | Spotify
An EY study shows that data and digital are transforming the life sciences industry. Hear from leaders how industry players can seize the upside of this disruption, and what it means for patient-consumers.
In EY Pulse of the industry, we examine the annual performance of the medical device industry in the context of the technological advances and rising customer expectations associated with the Fourth Industrial Revolution. To thrive in this transformative age, medtechs must adapt their business models to meet the increased expectations of consumers and other health stakeholders. Read more by visiting www.ey.com/pulse Additional audiobook formats include iTunes | Google Play Music | Spotify
In Life Sciences 4.0: securing value through data-driven platforms, we explore how health is being reimagined because of scientific and technological change and rising customer expectations. We also examine the ramifications for life sciences companies' market offerings, business models and the new capabilities needed as the disciplines of health care and technology merge to become "health technology". Read more by visiting us at ey.com/lifesciences Additional audiobook formats include iTunes | Google Play Music | Spotify
Comments
Download from Google Play
Download from App Store
United States